Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAND
NCT04522739Phase 4Completed
- Sponsor
- Emory University
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone in Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), sponsored by Emory University. Started Sep 2022; status: completed.
02
Drugs
spironolactone
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04522739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522739.